IND Application

February 13, 2019

Another knock back for urea cycle disorders

Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.

Lilly plays it by ear

Another knock back for urea cycle disorders

Regenerating insulin-producing cells the next big thing in diabetes

Better late than never for Maxcyte’s one-day CAR-T approach

Double trouble sinks Oncomed as investors look to earlier assets

Patent twists and turns make Crispr no easier to value

Therapy focus – Curis thinks small to hit big immuno-oncology target

First human Crispr trial is a go, but don’t ask about the IP

Interview – Enterome has a good gut feeling about 2016

Therapeutic focus – Astra goes ROR fishing and hooks Orca

Interview – GW Pharma eyes breakthrough therapy as epilepsy data approach

Latest Reports

Pharma Market Drivers Part Three: Blowin’ in the wind

Q3 Round Up: Alive but not kicking report

Editor's Picks

Lecanemab can; now the wait for details begins

The gloom deepens for biopharma stocks

SITC 2022 preview – cytokines and oral checkpoints

Big pharma’s key fourth-quarter data

TCT 2022 – Otsuka’s renal denervation system shines